People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity due to the amount of weight people lose while taking the injections.

But news about its Zepbound drug, along with lowered profit guidance, hurt the shares. The company's new oral GLP-1 drug, which avoids the use of injections, has huge potential. The company's GLP ...

Large employers can still customize coverage plans to include Zepbound. Analysts are increasingly betting that Eli Lilly will win the obesity race in the long-term. Is Eli Lilly’s Zepbound Super ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

Caissa Troutman, MD, recently treated a patient in her early 50s who she planned to prescribe the anti-obesity medication Zepbound. The patient’s insurance covered Zepbound but required prior ...

With anti-obesity injections dominating conversations, it's no surprise the conversation around their impact is growing. A ...

However, Wegovy has lost significant market share to rival Eli Lilly‘s (NYSE:LLY) Zepbound, because it is seen as a better, more efficacious GLP-1 drug. Zepbound’s active ingredient ...

But the rising popularity of GLP-1 drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound hit demand for its traditional weight-loss programmes. The company also acquired a telehealth ...